Company Profile

Sagimet Biosciences Stock Price, News & Catalysts

Ticker:
SGMT
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

9.62 USD (-4.85%)

Close

Last updated: November 19, 2026

419M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SGMT closed down 4.85% at $9.62. No new same-company headline was identified in the current news window.

Company overview

Metabolic Pathway Therapeutics

Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.

Denifanstat

Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.

Dermatology Focus

Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.

U.S. Acne Registration Strategy

Sagimet has initiated the U.S. AURORA Phase 3 program after positive denifanstat Phase 3 results from its Chinese license partner, while advancing a second FASN inhibitor into mid-stage acne development.

Future catalysts

  • Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.
  • Topline data from the U.S. Phase 3 AURORA study of denifanstat in the second half of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Sagimet Biosciences (SGMT)?

Sagimet Biosciences (SGMT) most recently closed at 9.62 USD, a -4.85% move versus the previous session.

What is the market cap of Sagimet Biosciences (SGMT)?

Sagimet Biosciences currently has a market capitalization of 419M USD on BioPharmSignal.

What does Sagimet Biosciences do?

Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing moderate-to-severe...

On which exchange is SGMT stock listed?

Sagimet Biosciences (SGMT) is associated with NASDAQ, United States, Biopharma.

What is TVB-3567?

Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.

Which conditions is Sagimet Biosciences targeting with TVB-3567?

Sagimet Biosciences is associated with metabolic disease, dermatology based on its company overview and current catalyst commentary.

How does Sagimet Biosciences describe recent progress with TVB-3567?

Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.

What is denifanstat?

Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.